Ετικέτες

Πέμπτη 13 Δεκεμβρίου 2018

Quality of life is significantly impaired in both secretory and non‐functioning pituitary adenomas

Summary

Objective

To evaluate the quality of life (QoL) in patients with pituitary adenomas in comparison with healthy Mexican population QoL scores.

Design & Measurements

Cross‐sectional study using the short form 36 questionnaire (SF‐36) in 175 patients with pituitary adenomas grouped by adenoma subtype and disease activity, and compared them with the healthy Mexican population normative QoL scores.

Patients

44 patients with non‐functioning pituitary adenomas (NFPA), 48 with acromegaly, 53 with prolactinomas and 30 with Cushing disease (CD) were enrolled in this study.

Results

Mental and physical components scores (MCS & PCS) of SF‐36 questionnaire were lower in patients with active disease in all adenoma subtypes (p<0.03). A significant negative relationship between prolactin levels and MCS (r= ‐0.30, p<0.01) and PCS (r=‐0.41, p<0.01) were found in prolactinomas. Patients with CD showed 24h urine free cortisol levels negatively correlated with MCS (r=‐0.43, p <0.01) but not with PCS. No significant correlation was found between IGF‐1ULN and QoL scores in acromegaly. NFPA patients had lower QoL scores than patients with controlled CD, acromegaly or prolactinoma (p <0.02). Active CD and prolactinoma have lower QoL scores in comparison of NFPA (p <0.05). Having an adenoma, secretory or non‐functional, decrease QoL scores in comparison of results in the healthy Mexican population register. Using an adjusted‐multivariate model, we confirmed that disease activity in all secretory adenomas is an independent risk factor, reducing SF‐36 scores significantly.

Conclusion

Activity in all secretory pituitary adenomas' patients decrease mental and physical QoL. However, independently of disease activity, secretory and NFPA significantly decrease QoL in comparison with healthy Mexican population QoL register.

This article is protected by copyright. All rights reserved.



https://ift.tt/2BgSFF7

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αναζήτηση αυτού του ιστολογίου